查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
基于 EV 的液体活检的全球市场 (2023-2032)：按服务细分、工作流程、样本类型、最终用户、技术和地区分類的分析、预测和竞争格局
市场调查报告书
商品编码
1318829

基于 EV 的液体活检的全球市场 (2023-2032)：按服务细分、工作流程、样本类型、最终用户、技术和地区分類的分析、预测和竞争格局

Global EV-Based Liquid Biopsy Market - A Global and Regional Analysis: Focus on Offering, Workflow, Sample Type, End User, Technology, Regional Analysis, and Competitive Landscape - Analysis and Forecast, 2023-2032
出版日期: | 出版商: BIS Research | 英文 166 Pages | 商品交期: 1-5个工作天内

价格
主要市场统计数据
开始年份 2023年
预测年份 2032
推出当年的市场规模 9009万美元（2023年）
市场规模预测 4.5553 亿美元（2032 年）
年复合成长率（%）： 19.73%

基于 EV 的液体活检：全球市场概述

预计到 2032 年，全球基于 EV 的液体活检市场规模将达到 4.5553 亿美元，预测期内年复合成长率为 19.73%，而 2022 年为 7822 万美元。

市场的增长预计将由持续的技术进步、医疗保健提供者越来越多的采用以及对个性化医疗的日益关注来推动。

市场生命週期阶段

全球基于 EV 的液体活检市场正处于发展阶段，学术研究和市场产品批准不断增加。此外，基于EV的液体活检在个性化医疗和精准肿瘤学中的日益增长的用途预计也将推动市场的进一步扩张。

从提供的细分市场来看，试剂盒和检测细分市场将在 2022 年占据市场主导地位。隔离试剂盒、检测方法和配件的采用增加有助于该细分市场的增长。各种外泌体和 EV 分离套件用于执行各种程序和液体活检。

从技术角度来看，分离行业将在 2022 年占据市场主导地位。在分离技术中，沉淀已成为最常用的技术。从工作流程来看，样品製备领域将在 2022 年引领市场。按最终用户划分，学术和研究领域同年占据了最大的市场份额。这些机构主要从事生物标誌物鑑定、药物开发和靶向细胞分析等研究活动。

按地区划分，北美地区预计将在 2022 年占据市场主导地位，并在整个预测期内保持主导地位。另一方面，拥有多个新兴经济体的亚太地区预计在预测期内增长率最高，复合年复合成长率为21.64%。

主要公司简介

  • Abcam plc
  • Bio-Techne Corporation
  • Horiba Ltd.
  • Qiagen NV
  • Thermo Fisher Scientific, Inc.
  • Malvern Panalytical Ltd
  • Lonza Group AG
  • Revvity, Inc. (PerkinElmer, Inc.)
  • Takara Bio Inc.
  • Norgen Biotek Corp.

本报告考察了全球基于 EV 的液体活检市场，提供市场定义和概述、EV 隔离和分析方法、监管和报销环境、市场影响因素和市场机会分析以及市场规模趋势和预测。按类别详细分析以及地区、竞争状况、主要公司简介等。

目录

第1章定义

第2章调查范围

第3章调查方法

第4章市场概况

第5章EV 分离与分析技术

  • 概述
  • 分离技术
  • 分析方法

第6章行业考虑

  • 概述
  • 美国法律要求
  • 欧洲法律要求和框架
  • 亚太地区的法律要求和框架
  • 赎回场景

第7章市场动态

  • 概述
  • 影响分析
  • 市场促进因素
  • 市场抑制因素
  • 市场机会

第8章竞争格局

  • 竞争格局概览
  • 市场份额分析
  • 增长份额分析

第9章全球基于电动汽车的液体活检市场，按产品细分

  • 试剂盒检测
  • 服务
  • 设备

第10章全球基于 EV 的液体活检市场（按工作流程）

  • 样品製备
  • 顺序
  • 数据分析

第11章全球基于 EV 的液体活检市场（按技术）

  • 绝缘技术
    • 沉淀
    • 超速离心
    • 色谱法
  • 分析技术
    • NGS
    • PCR
    • 流式细胞仪

第12章全球基于 EV 的液体活检市场（按样本类型）

  • 血
  • 尿
  • 唾液
  • 其他的

第13章全球基于 EV 的液体活检市场（按最终用户）

  • 学术研究所
  • 製药和生物技术公司
  • 临床实验室

第14章全球基于 EV 的液体活检市场（按地区）

  • 北美
  • 欧洲
  • 亚太地区
  • 拉丁美洲/中东
  • 其他地区

第15章公司简介

  • 公司简介
Product Code: BHP1400SA

“Global EV-Based Liquid Biopsy Market to Reach $455.53 Million by 2032.”

Global EV-Based Liquid Biopsy Market Overview

The global EV-based liquid biopsy market was valued at $78.22 million in 2022 and is anticipated to reach $455.53 million by 2032, witnessing a CAGR of 19.73% during the forecast period 2023-2032. The global EV-based liquid biopsy market is expected to be driven by ongoing technological advancements, increasing adoption by healthcare providers, and a growing focus on personalized medicine.

KEY MARKET STATISTICS
Start Year:2023
Forecast Year2032
Start Value$90.09 Million in 2023
Forecast Value$455.53 Million by 2032
CAGR %19.73%

Market Lifecycle Stage

The global EV-based liquid biopsy market is in progressing phase, which can be attributed to the increase in academic research and approval of products in the market. Furthermore, the expanding applications of EV-based liquid biopsy in personalized medicine and precision oncology are projected to drive further market expansion.

Impact

The adoption of EV-based liquid biopsy has revolutionized disease diagnosis and monitoring, offering numerous benefits over traditional biopsy methods. Its non-invasiveness, real-time monitoring capabilities, and potential for early disease detection have transformed the field of healthcare diagnostics. By providing a less invasive and more accessible method for detecting and monitoring diseases, particularly cancer, EV-based liquid biopsy has improved patient experiences, reduced healthcare costs, and enhanced overall healthcare outcomes. In addition, the entry of several established players, such as Thermo Fisher Scientific Inc., QIAGEN N.V., and Bio-Techne Corporation, is expected to aid the market growth.

Furthermore, the growth of the EV-based liquid biopsy market has stimulated research and development activities, fostered collaborations between industry players and academic institutions, and generated economic opportunities.

Market Segmentation:

Segmentation 1: by Offering

  • Kits and Assays
  • Services
  • Instruments

Kits and Assays Segment to Dominate the Global EV-Based Liquid Biopsy Market (by Offering)

Based on offering, the kits and assays segment dominated the global EV-based liquid biopsy market in FY2022. The increasing adoption of isolation kits, assays, and accessories contributed to the prominence of this segment. Various exosome and EV isolation kits are being used to carry out several procedures and liquid biopsy tests.

Segmentation 2: by Technology

  • Isolation
  • Analysis

Isolation Segment to Dominate the Global EV-Based Liquid Biopsy Market (by Technology)

Based on technology, the isolation segment dominated the global EV-based liquid biopsy market in FY2022. Under isolation technology, precipitation emerged as the most common technology used.

Segmentation 3: by Workflow

  • Sample Preparation
  • Sequencing
  • Data Analysis

Sample Preparation Segment to Dominate the Global EV-Based Liquid Biopsy Market (by Workflow)

Based on workflow, the EV-based liquid biopsy market was dominated by the sample preparation segment in FY2022. The sample preparation or pre-analytical phase in the EV-based liquid biopsy workflow includes specimen collection, stabilization, transport, enrichment, processing, isolation, and quality assessment of the analyte.

Segmentation 4: by End User

  • Academic and Research Institutes
  • Clinical Laboratories
  • Pharmaceutical and Biotechnology Companies

Academic and Research Institutes Segment to Dominate the Global EV-Based Liquid Biopsy Market (by End User)

Based on end user, academic and research segment accounted for the largest share of the global EV-based liquid biopsy market in FY2022. Academic and research institutes play a vital role in the adoption of EV-based liquid biopsy methods, serving as essential facilities for both companies and independent academic research. These institutions are primarily engaged in research activities aimed at identifying biomarkers, developing drugs, and conducting cell analysis to acquire targets.

Segmentation 5: by Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America and Middle East
  • Rest-of-the-World

In 2022, the North America region dominated the global EV-based liquid biopsy market, and it is expected to hold its dominance throughout the forecast period 2023-2032. However, the Asia-Pacific (APAC) region, constituting several emerging economies, is expected to register the highest CAGR of 21.64% in the market during the forecast period 2023-2032.

Demand - Drivers, Restraints, and Opportunities

Market Demand Drivers:

  • Abundance and Remarkable Stability of Exosomes Compared to CfDNA or CTCs
  • Amplified Funding and Dedicated Research Efforts
  • Increasing Prevalence of Cancers

Market Restraints:

  • Lack of Standardized EV Isolation and Characterization Protocols
  • Lack of Precise EV Subtype Classification and Biomarkers Validation

Market Opportunities:

  • Advancements in EV-Based Liquid Biopsy Technologies
  • Development of New EV-Based Biomarkers
  • Approved Products in the Market

How can this report add value to an organization?

  • Workflow/Innovation Strategy: The EV-based liquid biopsy market (by offering) has been segmented into kits and assays, instruments, and services. Moreover, the study provides the reader with a detailed understanding of the different types of technologies, end-users, and sample types used in these tests.
  • Growth/Marketing Strategy: EV-based liquid biopsy has tremendous growth potential due to its ability to revolutionize non-invasive cancer detection and monitoring. By analyzing the cargo of Evs, researchers can gain insights into the presence, type, and characteristics of tumors without directly accessing the tumor site.
  • Competitive Strategy: Key players in the EV-based liquid biopsy market have been analyzed and profiled in the study, including manufacturers. Moreover, a detailed competitive benchmarking of the players operating in the EV-based liquid biopsy market has been done to help the reader understand how players stack against each other, presenting a clear market landscape.

Key Market Players and Competition Synopsis

EV-based liquid biopsy refers to the use of extracellular vesicles (Evs) as a non-invasive diagnostic tool for detecting and monitoring various diseases, including cancer. The global EV-based liquid biopsy market has experienced substantial growth driven by technological advancements, rising demand for non-invasive diagnostics, and the global increase in cancer prevalence.

Key Companies Profiled:

  • Abcam plc
  • Bio-Techne Corporation
  • Horiba Ltd.
  • Qiagen N.V.
  • Thermo Fisher Scientific, Inc.
  • Malvern Panalytical Ltd
  • Lonza Group AG
  • Revvity, Inc. (PerkinElmer, Inc.)
  • Takara Bio Inc.
  • Norgen Biotek Corp.

Table of Contents

1 Definition

  • 1.1 Inclusion and Exclusion Criteria

2 Research Scope

  • 2.1 Target Audience
  • 2.2 Key Questions Answered in the Report:

3 Research Methodology

  • 3.1 Global EV-Based Liquid Biopsy Market: Research Methodology
  • 3.2 Primary Data Sources
  • 3.3 Secondary Data Sources
  • 3.4 Market Estimation Model
  • 3.5 Criteria for Company Profiling

4 Markets Overview

  • 4.1 Market Introduction
  • 4.2 Current and Future State of EV-Based Liquid Biopsy in Industries
  • 4.3 Current Market Size and Growth Potential, $Million, 2022-2032
  • 4.4 COVID-19 Impact on Global EV-based Liquid Biopsy Market
    • 4.4.1 Impact on Operations
    • 4.4.2 COVID-19 Impact: Current Scenario of the Market

5 Methods of EV Isolation and Analysis

  • 5.1 Overview
    • 5.1.1 Evs Introduction
  • 5.2 Isolation Methods
    • 5.2.1 EV Isolation Techniques Utilizing Ultracentrifugation Methods
      • 5.2.1.1 Differential Ultracentrifugation
      • 5.2.1.2 Density Gradient Centrifugation
      • 5.2.1.3 Moving Zone or Rate-Zonal Centrifugation
      • 5.2.1.4 Isopycnic Centrifugation
    • 5.2.2 EV Isolation Techniques Utilizing Size-Based Methods
      • 5.2.2.1 Ultrafiltration
      • 5.2.2.2 Sequential Filtration
      • 5.2.2.3 Size Exclusion Chromatography (SEC)
      • 5.2.2.4 Flow Field-Flow Fractionation (FFFF)
      • 5.2.2.5 Hydrostatic Filtration Dialysis (HFD)
    • 5.2.3 EV Isolation Techniques Utilizing Immunoaffinity Methods
      • 5.2.3.1 Enzyme-Linked Immunosorbent Assay (ELISA)
      • 5.2.3.2 Magneto-Immunoprecipitation
    • 5.2.4 EV Isolation Techniques Utilizing Precipitation Methods
      • 5.2.4.1 Polyethylene Glycol (PEG) Precipitation
      • 5.2.4.2 Lectin Induced Agglutination
    • 5.2.5 EV Isolation Techniques Utilizing Microfluidic Technology
    • 5.2.6 EV Isolation Techniques Utilizing Commercial Kits
    • 5.2.7 Advantages and Disadvantages of the EV Isolation Methods
    • 5.2.8 Novel Approaches for Exosome Isolation
  • 5.3 Analysis Methods
    • 5.3.1 Advantages and Disadvantages of Analysis Methods for Evs

6 Industry Insights

  • 6.1 Overview
  • 6.2 Legal Requirements in the U.S.
  • 6.3 Legal Requirements and Frameworks in Europe
  • 6.4 Legal Requirements and Frameworks in Asia-Pacific
  • 6.5 Reimbursement Scenario

7 Market Dynamics

  • 7.1 Overview
  • 7.2 Impact Analysis
  • 7.3 Market Drivers
    • 7.3.1 Abundance and Remarkable Stability of Exosomes Compared to CfDNA or CTCs
    • 7.3.2 Amplified Funding and Dedicated Research Efforts
    • 7.3.3 Rising Prevalence of Cancers
  • 7.4 Market Restraints
    • 7.4.1 Lack of Standardized EV Isolation and Characterization Protocols
    • 7.4.2 Lack of Precise EV Subtype Classification and Biomarkers Validation
  • 7.5 Market Opportunities
    • 7.5.1 Advancements in EV-Based Liquid Biopsy Technologies
    • 7.5.2 Development of New EV-Based Biomarkers
    • 7.5.3 Approved Products in the Market

8 Competitive Landscape

  • 8.1 Competitive Landscape Overview
    • 8.1.1 Key Developments
    • 8.1.2 Product Launches and Expansion Activities
    • 8.1.3 Merger and Acquisition Activities
    • 8.1.4 Synergistic Activities
    • 8.1.5 License and Agreement Activities
    • 8.1.6 Other Activities
  • 8.2 Market Share Analysis (2022)
  • 8.3 Growth-Share Analysis (2021-2022)
    • 8.3.1 Growth-Share Analysis (by Company)

9 Global EV-Based Liquid Biopsy Market (by Offering),$Million, 2022-2032

  • 9.1 Overview
  • 9.2 Kits and Assays
  • 9.3 Services
  • 9.4 Instruments

10 Global EV-Based Liquid Biopsy Market (by Workflow), $Million, 2022-2032

  • 10.1 Overview
    • 10.1.1 Sample Preparation
    • 10.1.2 Sequencing
    • 10.1.3 Data Analysis

11 Global EV-Based Liquid Biopsy Market (by Technology), $Million, 2022-2032

  • 11.1 Overview
  • 11.2 Isolation Technologies
    • 11.2.1 Precipitation
    • 11.2.2 Ultracentrifugation
    • 11.2.3 Chromatography
  • 11.3 Analysis Technologies
    • 11.3.1 NGS
    • 11.3.2 PCR
    • 11.3.3 Flow Cytometry

12 Global EV-Based Liquid Biopsy Market (by Sample Type), $Million, 2022-2032

  • 12.1 Overview
    • 12.1.1 Blood
    • 12.1.2 Urine
    • 12.1.3 Saliva
    • 12.1.4 Other Biofluids

13 Global EV-Based Liquid Biopsy Market (by End User), $Million, 2022-2032

  • 13.1 Overview
  • 13.2 Academic and Research Institutes
  • 13.3 Pharmaceutical and Biotechnology Companies
  • 13.4 Clinical Laboratories

14 Global EV-Based Liquid Biopsy Market (by Region), $Million, 2022-2032

  • 14.1 Overview
  • 14.2 North America
    • 14.2.1 U.S.
    • 14.2.2 Canada
  • 14.3 Europe
    • 14.3.1 Germany
    • 14.3.2 U.K.
    • 14.3.3 France
    • 14.3.4 Italy
    • 14.3.5 Spain
    • 14.3.6 Rest-of-Europe
  • 14.4 Asia-Pacific
    • 14.4.1 China
    • 14.4.2 Japan
    • 14.4.3 India
    • 14.4.4 South Korea
    • 14.4.5 Australia
    • 14.4.6 Singapore
    • 14.4.7 Rest-of-Asia-Pacific
  • 14.5 Latin America and Middle East
    • 14.5.1 Brazil
    • 14.5.2 Mexico
    • 14.5.3 Saudi Arabia
    • 14.5.4 Rest-of-Latin America and Middle East
  • 14.6 Rest-of-the-World

15 Company Profiles

  • 15.1 Company Overview
    • 15.1.1 Abcam plc
      • 15.1.1.1 Company Overview
      • 15.1.1.2 Role of Abcam plc in the Global EV-Based Liquid Biopsy Market
      • 15.1.1.3 Major Products: Key Specifications
      • 15.1.1.4 Key Competitors
      • 15.1.1.5 Analyst Perspective
    • 15.1.2 Bio-Techne Corporation
      • 15.1.2.1 Company Overview
      • 15.1.2.2 Role of Bio-Techne Corporation in the Global EV-Based Liquid Biopsy Market
      • 15.1.2.3 Major Products: Key Specifications
      • 15.1.2.4 Key Competitors
      • 15.1.2.5 Analyst Perspective
    • 15.1.3 Horiba Ltd.
      • 15.1.3.1 Company Overview
      • 15.1.3.2 Role of Horiba Ltd. in the Global EV-Based Liquid Biopsy Market
      • 15.1.3.3 Major Products: Key Specifications
      • 15.1.3.4 Key Competitors
      • 15.1.3.5 Analyst Perspective
    • 15.1.4 Qiagen N.V.
      • 15.1.4.1 Company Overview
      • 15.1.4.2 Role of Qiagen N.V. in the Global EV-Based Liquid Biopsy Market
      • 15.1.4.3 Major Products: Key Specifications
      • 15.1.4.4 Key Competitors
      • 15.1.4.5 Analyst Perspective
    • 15.1.5 Thermo Fisher Scientific, Inc.
      • 15.1.5.1 Company Overview
      • 15.1.5.2 Role of Thermo Fisher Scientific, Inc. in the Global EV-Based Liquid Biopsy Market
      • 15.1.5.3 Major Products: Key Specifications
      • 15.1.5.4 Key Competitors
      • 15.1.5.5 Analyst Perspective
    • 15.1.6 Malvern Panalytical Ltd
      • 15.1.6.1 Company Overview
      • 15.1.6.2 Role of Malvern Panalytical Ltd in the Global EV-Based Liquid Biopsy Market
      • 15.1.6.3 Major Products: Key Specifications
      • 15.1.6.4 Key Competitors
      • 15.1.6.5 Analyst Perspective
    • 15.1.7 Lonza Group AG
      • 15.1.7.1 Company Overview
      • 15.1.7.2 Role of Lonza Group AG in the Global EV-Based Liquid Biopsy Market
      • 15.1.7.3 Major Products: Key Specifications
      • 15.1.7.4 Key Competitors
      • 15.1.7.5 Analyst Perspective
    • 15.1.8 Revvity, Inc. (PerkinElmer, Inc.)
      • 15.1.8.1 Company Overview
      • 15.1.8.2 Role of Revvity, Inc. (PerkinElmer Inc.) in the Global EV-Based Liquid Biopsy Market
      • 15.1.8.3 Major Products: Key Specifications
      • 15.1.8.4 Key Competitors
      • 15.1.8.5 Analyst Perspective
    • 15.1.9 Takara Bio Inc.
      • 15.1.9.1 Company Overview
      • 15.1.9.2 Role of Takara Bio Inc. in the Global EV-Based Liquid Biopsy Market
      • 15.1.9.3 Major Products: Key Specifications
      • 15.1.9.4 Key Competitors
      • 15.1.9.5 Analyst Perspective
    • 15.1.10 Norgen Biotek Corp.
      • 15.1.10.1 Company Overview
      • 15.1.10.2 Role of Norgen Biotek Corp. in the Global EV-Based Liquid Biopsy Market
      • 15.1.10.3 Major Products: Key Specifications
      • 15.1.10.4 Key Competitors
      • 15.1.10.5 Analyst Perspective
    • 15.1.11 Emerging Companies
      • 15.1.11.1 Mursla Bio
      • 15.1.11.2 Nanostics Inc.
      • 15.1.11.3 Mercy BioAnalytics, Inc.
      • 15.1.11.4 Clara Diagnostics, Inc. (Clara Biotech)

List of Figures

  • Figure 1: Global EV-Based Liquid Biopsy Market (by Offering), $Million, 2022-2032
  • Figure 2: Global EV-Based Liquid Biopsy Market (by End User), $Million, 2022 and 2032
  • Figure 3: Global EV-Based Liquid Biopsy Market (by Region), 2022
  • Figure 4: Global EV-Based Liquid Biopsy Market Segmentation
  • Figure 5: Global EV-Based Liquid Biopsy Market Regional Segmentation
  • Figure 6: Global EV-Based Liquid Biopsy Market Methodology
  • Figure 7: Primary Research Methodology
  • Figure 8: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 9: Top-Down Approach (Segment-Wise Analysis)
  • Figure 10: Global EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 11: Subtypes of Evs
  • Figure 12: Methods of EV-Isolation from Biofluids
  • Figure 13: Workflow of Differential Ultracentrifugation for Exosome Isolation
  • Figure 14: Methods of EV-Analysis
  • Figure 15: Global EV-Based Liquid Biopsy Market - Market Dynamics
  • Figure 16: Structure of Evs Enveloped by Protective Lipid Membrane
  • Figure 17: Number of Research Publications on Exosomes, 2015-2021
  • Figure 18: Share of New Cancer Cases, 2020
  • Figure 19: Number of Cancer Cases, 2020
  • Figure 20: Currently Investigated Circulating Biomarkers Associated with Evs
  • Figure 21: Share of Key Developments and Strategies, January 2019-June 2023
  • Figure 22: Share of Product Launch and Expansion Activities (by Company), January 2019-June 2023
  • Figure 23: Share of Synergistic Activities (by Company), January 2019-June 2023
  • Figure 24: Share of Other Activities (by Company), January 2019-June 2023
  • Figure 25: Market Share Analysis for Global EV-Based Liquid Biopsy Market, 2022
  • Figure 26: Growth-Share Analysis for Global EV-Based Liquid Biopsy Market (by Company), 2021-2022
  • Figure 27: Global EV-Based Liquid Biopsy Market (by Offering), $Million, 2022-2032
  • Figure 28: Global EV-Based Liquid Biopsy Market (Kits and Assays), $Million, 2022-2032
  • Figure 29: Global EV-Based Liquid Biopsy Market (Services), $Million, 2022-2032
  • Figure 30: Global EV-Based Liquid Biopsy Market (Instruments), $Million, 2022-2032
  • Figure 31: Global EV-Based Liquid Biopsy Market (by Workflow), $Million, 2022 and 2032
  • Figure 32: Global EV-Based Liquid Biopsy Market (Sample Preparation), $Million, 2022-2032
  • Figure 33: Global EV-Based Liquid Biopsy Market (Sequencing), $Million, 2022-2032
  • Figure 34: Global EV-Based Liquid Biopsy Market (Data Analysis), $Million, 2022-2032
  • Figure 35: Global EV-Based Liquid Biopsy Market (by Technology)
  • Figure 36: Global EV-Based Liquid Biopsy Market (by Technology), $Million, 2022 and 2032
  • Figure 37: Global EV-Based Liquid Biopsy Market (Isolation Technologies), $Million, 2022-2032
  • Figure 38: Global EV-Based Liquid Biopsy Market (Precipitation), $Million, 2022-2032
  • Figure 39: Global EV-Based Liquid Biopsy Market (Ultracentrifugation), $Million, 2022-2032
  • Figure 40: Global EV-Based Liquid Biopsy Market (Chromatography), $Million, 2022-2032
  • Figure 41: Global EV-Based Liquid Biopsy Market (Analysis Technologies), $Million, 2022-2032
  • Figure 42: Global EV-Based Liquid Biopsy Market (NGS), $Million, 2022-2032
  • Figure 43: Global EV-Based Liquid Biopsy Market (PCR), $Million, 2022-2032
  • Figure 44: Global EV-Based Liquid Biopsy Market (Flow Cytometry), $Million, 2022-2032
  • Figure 45: Global EV-Based Liquid Biopsy Market (by Sample Type)
  • Figure 46: Global EV-Liquid Biopsy Market (by Sample Type), $Million, 2022 and 2032
  • Figure 47: Global EV-Based Liquid Biopsy Market (Blood), $Million, 2022-2032
  • Figure 48: Global EV-Based Liquid Biopsy Market (Urine), $Million, 2022-2032
  • Figure 49: Global EV-Based Liquid Biopsy Market (Saliva), $Million, 2022-2032
  • Figure 50: Global EV-Based Liquid Biopsy Market (Other Biofluids), $Million, 2022-2032
  • Figure 51: Global EV-Based Liquid Biopsy Market (by End User)
  • Figure 52: Global EV-Based Liquid Biopsy Market (by End User), $Million, 2022 and 2032
  • Figure 53: Global EV-Based Liquid Biopsy Market (Academic and Research Institutes), $Million, 2022-2032
  • Figure 54: Global EV-Based Liquid Biopsy Market (Pharmaceutical and Biotechnology Companies), $Million, 2022-2032
  • Figure 55: Global EV-Based Liquid Biopsy Market (Clinical Laboratories), $Million, 2022-2032
  • Figure 56: Global EV-Based Liquid Biopsy Market Snapshot (by Region)
  • Figure 57: Global EV-Based Liquid Biopsy Market (by Region), $Million, 2022-2032
  • Figure 58: North America EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 59: North America: Market Dynamics
  • Figure 60: North America EV-Based Liquid Biopsy Market (by Country), $Million, 2022-2032
  • Figure 61: U.S. EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 62: Canada EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 63: Europe EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 64: Europe: Market Dynamics
  • Figure 65: Europe EV-Based Liquid Biopsy Market (by Country), $Million, 2022-2032
  • Figure 66: Germany EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 67: U.K. EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 68: France EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 69: Italy EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 70: Spain EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 71: Rest-of-Europe EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 72: Asia-Pacific EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 73: Asia-Pacific: Market Dynamics
  • Figure 74: Asia-Pacific EV-Based Liquid Biopsy Market (by Country), $Million, 2022-2032
  • Figure 75: China EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 76: Japan EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 77: India EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 78: South Korea EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 79: Australia EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 80: Singapore EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 81: Rest-of-Asia-Pacific EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 82: Latin America and Middle East EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 83: Latin America and Middle East: Market Dynamics
  • Figure 84: Latin America and Middle East EV-Based Liquid Biopsy Market (by Country), $Million, 2022-2032
  • Figure 85: Brazil EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 86: Mexico EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 87: Saudi Arabia EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 88: Rest-of-Latin America and Middle East EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 89: Rest-of-the-World EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 90: Total Number of Companies Profiled
  • Figure 91: Abcam plc: Product Portfolio
  • Figure 92: Bio-Techne Corporation: Product Portfolio
  • Figure 93: Horiba Ltd.: Product Portfolio
  • Figure 94: Qiagen N.V.: Product Portfolio
  • Figure 95: Thermo Fisher Scientific, Inc.: Product Portfolio
  • Figure 96: Malvern Panalytical Ltd: Product Portfolio
  • Figure 97: Lonza Group AG: Product Portfolio
  • Figure 98: Revvity, Inc. (PerkinElmer Inc.): Product Portfolio
  • Figure 99: Takara Bio Inc.: Product Portfolio
  • Figure 100: Norgen Biotek Corp.: Product Portfolio

List of Tables

  • Table 1: Current and Future State of EV-Based Liquid Biopsy in Industries
  • Table 2: Example of Few Commercial Kits Available for EV Isolation
  • Table 3: Advantages and Disadvantages of the EV Isolation Methods
  • Table 4: Emerging Methods for the Isolation of Exosomes
  • Table 5: Advantages and Disadvantages of Analysis Methods for Evs
  • Table 6: Legal Requirements in the U.S.
  • Table 7: Legal Landscape for EV-Based Liquid Biopsies in Europe
  • Table 8: Size and Densities of Evs and Various Lipoproteins
  • Table 9: Technological Advancements in EV-Based Liquid Biopsy